This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sader, H. S. Articles by Jones, R. N. Search for Related Content PubMed PubMed Citation Articles by Sader, H. S. Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3501-3512, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3501-3512.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

JMI Laboratories, North Liberty, Iowa,¹ Universidade Federal de São Paulo, São Paulo, Brazil,² Peninsula Pharmaceuticals, Alameda, California,³ Tufts University School of Medicine, Boston, Massachusetts⁴

Received 8 February 2005/ Returned for modification 29 March 2005/ Accepted 15 May 2005

PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.